



December 2024

**PARKHA** 朴荷

\$4,800,000

Initial Public Offering

Underwriter



For more information please contact :

### Investment Banking

Stephanie Hu  
Co-Head, Investment Banking  
Direct: +1 (929) 586-0272  
shu@dboralcapital.com

Gaurav Verma  
Co-Head, Investment Banking  
Direct: +1 (929) 528-0912  
gverma@dboralcapital.com

Ryan Zhang  
Vice President  
Direct: +1 (929) 528-0992  
rzhang@dboralcapital.com

### Equity Capital Markets

Philip Wiederlight  
Chief Operating Officer  
Direct: +1 (929) 625-1539  
pwiederlight@dboralcapital.com

Mark Iorio  
Director, Equity Capital Markets  
Direct: +1 (929) 528-0913  
miorio@dboralcapital.com

## D. Boral Capital Served as Underwriter to Park Ha Biological Technology Co., Ltd. (Nasdaq: PHH) in connection with its \$4.8 Million Initial Public Offering

### Transaction Information

Wuxi, China, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Park Ha Biological Technology Co., Ltd. (the "Company"), a company focused on developing private skincare labels, direct skincare product sales, and franchise alliance promotions, today announced the pricing of its initial public offering (the "Offering") of 1,200,000 ordinary shares at a public offering price of \$4.00 per ordinary share. The ordinary shares have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on December 27, 2024 under the ticker symbol "PHH."

The Company expects to receive aggregate gross proceeds of \$4.8 million from the Offering, before deducting underwriting discounts and other related expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 180,000 ordinary shares at the public offering price, less underwriting discounts. The Offering is expected to close on or about December 30, 2024, subject to the satisfaction of customary closing conditions.

Net proceeds from the Offering will be used for (i) expanding the scale of directly-owned stores in the PRC; (ii) purchasing existing product patents to develop proprietary products; and (iii) acquiring ingredient suppliers to reduce production costs over the long term.

### About Park Ha Biological Technology Co., Ltd.

Established in 2016, Park Ha Biological Technology Co., Ltd. is primarily engaged in developing its private skincare label, direct skincare products sales and franchise alliances promotions under the proprietary brand "Park Ha", with a commitment to providing cost-effective solutions to skin problems and improving the confidence of women in need of skin treatment. As of April 30, 2024, the Company has two directly operated stores and 43 franchisees, of which 41 and two operate under the store name "Park Ha" and "Geni" respectively, in China. As part of its value-added service for the products, the Company offers "light beauty experience", a quick complimentary after-sales beauty service performed in the directly-operated stores and franchise stores. For more information, please visit the Company's website: <http://ir.parkha.cn/>.

### About D. Boral Capital

D. Boral Capital LLC is an investment bank headquartered in New York which provides advisory and financing solutions to middle market and emerging growth companies. The Company has a proven track record of offering strategic guidance to clients across the globe in any sector, with access to capital from the USA, Asia, Europe, UAE, and Latin America.

D. Boral Capital is a leader on Wall Street, having aggregated over \$23 billion in capital across approximately 300 transactions through various product types.

